Aptose Biosciences Inc. (NASDAQ:APTO)‘s stock had its “buy” rating reissued by Roth Capital in a note issued to investors on Friday. They currently have a $8.00 price target on the stock. Roth Capital’s target price points to a potential upside of 263.64% from the company’s previous close.
Several other research analysts have also recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Saturday. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. RBC Capital Markets reissued an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $23.00 target price on shares of Aptose Biosciences in a report on Saturday, June 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.20 on Friday. The company’s market capitalization is $28.36 million. The firm’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.46. Aptose Biosciences has a one year low of $1.92 and a one year high of $6.40.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned about 0.43% of Aptose Biosciences as of its most recent SEC filing. 19.47% of the stock is owned by institutional investors and hedge funds.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.